Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results

MT Newswires Live

2024/12/26

Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced "encouraging" safety and efficacy results in patients with chronic hepatitis B virus.

The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.

The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.

The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.

Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.

Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2494868612"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494868612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494868612?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-26 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494868612","market":"nz","top_or_hot":-1,"title":"Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results","media":"MT Newswires Live","content":"<html><body><p> Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.</p><p>The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.</p><p>The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.</p><p>The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.</p><p>Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.</p><p>Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-12-26 21:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.</p><p>The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.</p><p>The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.</p><p>The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.</p><p>Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.</p><p>Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4578","symbol_name":"CAR-T","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2494868612","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494868612","pubTimestamp":1735220259,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Assembly Biosciences  said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.Following completion of the phase 1b study, Gilead Sciences  has the right to opt in to further development and commercialization of the drug, the company said.Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4578":"CAR-T","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4568":"美国抗疫概念","GILD":"吉利德科学","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4550":"红杉资本持仓","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","ASMB":"Assembly Biosciences Inc.","BK4583":"猴痘概念","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4532":"文艺复兴科技持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4566":"资本集团","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4585":"ETF&股票定投概念","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"Assembly Biosciences表示抗病毒药物显示出“令人鼓舞”的第一阶段结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASMB":1,"GILD":0.9},"content_text":"Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}